Literature DB >> 24836818

Laparoscopic Roux-en-Y gastric bypass for treatment of symptomatic paraesophageal hernia in the morbidly obese: medium-term results.

Umer I Chaudhry1, Brendan M Marr1, Sylvester N Osayi1, Dean J Mikami1, Bradley J Needleman1, W Scott Melvin1, Kyle A Perry2.   

Abstract

BACKGROUND: The ideal surgical approach for treatment of symptomatic paraesophageal hernias (PEH) in obese patients remains elusive. The objective of this study was to assess the safety, feasibility, and effectiveness of combined laparoscopic PEH repair and Roux-en-Y gastric bypass (RYGB) for the management of symptomatic PEH in morbidly obese patients.
METHODS: Fourteen patients with symptomatic PEH and morbid obesity (body mass index [BMI]>35 kg/m(2)) underwent laparoscopic PEH repair with RYGB between 2008 and 2011. Demographic characteristics and preoperative and perioperative details were analyzed. Patients were contacted in October 2013 for follow-up. BMI, reflux symptoms, and disease-specific quality of life (QoL) data were obtained.
RESULTS: There were 11 females (79%). Median age and preoperative BMI were 48 years and 42 kg/m(2), respectively. Mean operative time was 180 minutes, with median length-of-stay of 4 days. There were no perioperative deaths, and 5 patients experienced postoperative complications including 1 gastrojejunostomy leak. Complete follow-up with a median follow-up interval of 35 months was available in 9 (64%) patients. The median % excess weight loss was 67.9%. Thirty-three percent required antisecretory medications for reflux control, compared to 89% preoperatively. Seventy-eight percent of patients reported good to excellent QoL outcomes assessed by the Gastroesophageal Reflux Disease Health-Related Quality of Life questionnaire. Overall, 89% of patients were satisfied with their operation and would undergo the procedure again.
CONCLUSION: Combined laparoscopic PEH repair and RYGB is a safe, feasible, and effective treatment option for morbidly obese patients with symptomatic PEH, and offers good to excellent disease-specific quality-of-life outcomes at medium-term follow-up. To date, this is the largest series with the longest follow-up in this unique patient population.
Copyright © 2014 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Morbid obesity; Paraesophageal hernia; Roux-en-Y gastric bypass

Mesh:

Year:  2014        PMID: 24836818     DOI: 10.1016/j.soard.2014.02.004

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  5 in total

1.  Combining laparoscopic giant paraesophageal hernia repair with sleeve gastrectomy in obese patients.

Authors:  Ankit D Patel; Edward Lin; Nathaniel W Lytle; Juan P Toro; Jahnavi Srinivasan; Arvinpal Singh; John F Sweeney; S Scott Davis
Journal:  Surg Endosc       Date:  2014-08-27       Impact factor: 4.584

Review 2.  The Optimal Approach to Symptomatic Paraesophageal Hernia Repair: Important Technical Considerations.

Authors:  Jessica A Zaman; Anne O Lidor
Journal:  Curr Gastroenterol Rep       Date:  2016-10

3.  Roux-en-Y Gastrojejunostomy: is it an effective treatment for complex Hiatal hernias in the morbidly obese?

Authors:  Shankar I Logarajah; Jashwanth Karumuri; David Ahle; Michael Jureller; Maitham Moslim; Houssam Osman; D Rohan Jeyarajah
Journal:  Surg Endosc       Date:  2022-08-19       Impact factor: 3.453

4.  Concurrent Large Para-oesophageal Hiatal Hernia Repair and Laparoscopic Adjustable Gastric Banding: Results from 5-year Follow Up.

Authors:  Andrew J Long; Paul R Burton; Cheryl P Laurie; Margaret L Anderson; Geoff S Hebbard; Paul E O'Brien; Wendy A Brown
Journal:  Obes Surg       Date:  2016-05       Impact factor: 4.129

5.  Simultaneous Large Paraesophageal Hernia Repair and Laparoscopic Roux-en-Y Gastric Bypass: a Single Institution's Experience.

Authors:  Y G A Brammerloo; J C Hol; C M Theunissen; B S Langenhoff
Journal:  Obes Surg       Date:  2019-04       Impact factor: 4.129

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.